TransCode Therapeutics, Inc

RNAZNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

1.01M

on 2026-06-30, from 6,286 on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-33 and 1-for-28 reverse splits; each bar's tip shows the count as filed.

Newest

$150.0M

S-3 of 2025-12-12. None sold under it to 2026-10-05. S-3 ↗

$14.0M

YA II PN, agreement of 2026-10-01. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

The 10-Q filed 2026-08-14 is not read yet.

Cash

1.5 quarters

$8.4M on 2026-06-30 ÷ $5.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 13 of its filings are not read yet.